US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

888.98

-20.6613-2.27%

Number of Gainers:55

Number of Losers:111

Number of Flat:10

PE:- -

High:925.65

Open:909.64

Low:888.04

Close:909.64

Volume:364.83M

Turnover:13.04B

Market Cap:666.00B

Float Cap:475.56B

Loading ...

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Flywire General Counsel Peter Butterfield Reports Disposal of Common Shares

SentinelOne Updates Board Committee Assignment for New Director

BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition

Tenaya Therapeutics Announces Proposed Public Offering

FDA Lifts Clinical Hold on Tenaya Therapeutics’ MyPEAK-1 Trial

Tenaya Therapeutics Reports Positive Interim Results for TN-401 Gene Therapy in ARVC Trial

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for Mypeak-1™ Phase 1B/2a Clinical Trial of Tn-201 Gene Therapy

THOMSON REUTERS

Tenaya Therapeutics Inc - Does Not Expect Hold to Impact Data Milestones

THOMSON REUTERS

Tenaya Therapeutics Inc - Tn-401 Well Tolerated at 3E13 Vg/Kg Dose

THOMSON REUTERS

Tenaya Therapeutics Inc: Robust Transduction and Demonstrated Increases in Pkp2 Protein Levels in First Two Patients at Week 8

THOMSON REUTERS

Tenaya Therapeutics Inc - Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients With More Than Six Months of Follow-up

THOMSON REUTERS

Press Release: Oruka Therapeutics Announces New Board Member and Board Transition

Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

What's Going On With The Dip In SentinelOne Stock?

Prediction Markets Form Lobbying Group as State Pressure Ramps Up -- Barrons.com

JP Morgan Issues $50 Million Commercial Paper Debt On Solana

XRP Gets Yet Another ETF, But $2 Looks Like It's About To Break

How Weak November Metrics and Connecticut Probe At Robinhood (HOOD) Have Changed Its Investment Story

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4539/news?page=19"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":888.98,"timestamp":1766005199999,"preClose":909.6413,"halted":0,"volume":364829934,"delay":0,"changeRate":-0.022714,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-20.661316,"latestTime":"12-17 16:00:00 EST","open":909.64056,"high":925.6504,"low":888.0383,"amount":13036122183.732037,"amplitude":0.041348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766019600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.420989,"peRate":155.098356,"turnoverRate":0.026475,"increases":55,"decrements":111,"flats":6,"marketCap":666003713840.375,"floatMarketCap":475558281959.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":925.6504,"amplitude":0.041348,"preClose":909.6413,"low":888.0383,"pbRate":"7.420989","latestPrice":888.98,"volume":364829934,"delay":0,"open":909.64056,"prevYearClose":648.26935,"prevWeekClose":920.1564,"prevMonthClose":898.8388,"prevQuarterClose":1016.6711,"fiveDayClose":965.8891,"twentyDayClose":830.261,"sixtyDayClose":961.9245,"secType":"PLATE","market":"US","turnoverRate":0.026475,"peRate":155.098356,"marketCap":666003713840.375,"floatMarketCap":475558281959.875,"timestamp":1766005199999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":55,"down":111,"flat":10},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:19,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590562541","title":"Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry","url":"https://stock-news.laohu8.com/highlight/detail?id=2590562541","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590562541?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:15","pubTimestamp":1765487700,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.(“Serina” or the \"Company\") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204315/0/en/Serina-Therapeutics-Strengthens-Leadership-Team-with-Appointment-of-Dr-Joshua-Thomas-as-VP-Head-of-Chemistry.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","TISI","BK4007","BK4080","LENZ","BK4231","BK4139","ADC","BK4539"],"gpt_icon":0},{"id":"2590854922","title":"Flywire General Counsel Peter Butterfield Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590854922","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590854922?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:11","pubTimestamp":1765487464,"startTime":"0","endTime":"0","summary":"Peter Butterfield, General Counsel and Chief Compliance Officer of Flywire Corporation, reported a disposal of common shares of Flywire Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flywire Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLchd3F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Flywire General Counsel Peter Butterfield Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","FLYW","LU1815336091.USD","BK4227","LU0757428866.USD","BK4539","BK4106"],"gpt_icon":0},{"id":"2590260549","title":"SentinelOne Updates Board Committee Assignment for New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2590260549","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590260549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:10","pubTimestamp":1765487401,"startTime":"0","endTime":"0","summary":"SentinelOne Inc. has filed an amendment to its previous report to announce that Mark Barrenechea, appointed to the company's Board of Directors on December 3, 2025, has been named a member of the Nominating and Corporate Governance Committee, effective December 9, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SentinelOne Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1tdhpV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","BK4539","BK4588","LU2286300806.USD","BK4097","BK4585","S","BK4560"],"gpt_icon":0},{"id":"2590491445","title":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487138,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2590454151","title":"Tenaya Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454151","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590454151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:02","pubTimestamp":1765486920,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Dec.  11, 2025  (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204290/0/en/Tenaya-Therapeutics-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4531","TNYA","BK4585","BK4588","BK4139","BK4539","HCM"],"gpt_icon":0},{"id":"2590354996","title":"FDA Lifts Clinical Hold on Tenaya Therapeutics’ MyPEAK-1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590354996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590354996?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486878,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has lifted the clinical hold on its MyPEAK-1 Phase 1b/2a clinical trial of TN-201, a gene therapy being developed for the treatment of MYBPC3-associated hypertrophic cardiomyopathy. The decision follows Tenaya's successful resolution of all FDA concerns related to the hold. The company is now implementing protocol amendments agreed upon with the FDA and plans to resume dosing in collaboration with clinical sites. No new safety issues have been identified, and Tenaya does not expect the hold to affect its data milestones or development timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4T58RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","TNYA","LU0314104364.USD","BK4585","LU2210150020.SGD","BK4139","BK4539","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","BK4112","SG9999014013.SGD"],"gpt_icon":0},{"id":"2590499515","title":"Tenaya Therapeutics Reports Positive Interim Results for TN-401 Gene Therapy in ARVC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499515","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499515?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486876,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. announced positive interim results from Cohort 1 of the ongoing RIDGE-1 Phase 1b/2 clinical trial evaluating TN-401 gene therapy for adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy . According to the company, TN-401 was well tolerated at the 3E13 vg/kg dose, with robust gene transduction and increased PKP2 protein levels observed in the first two patients at week 8. Clinically meaningful reductions in arrhythmia burden were reported in the first two patients with more than six months of follow-up. Tenaya Therapeutics plans to present these preliminary results during a webcast conference call on December 11, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1vHmXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","TNYA","BK4112","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","NDAQ","SG9999014039.USD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","BK4539"],"gpt_icon":0},{"id":"2590935549","title":"Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for Mypeak-1™ Phase 1B/2a Clinical Trial of Tn-201 Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590935549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590935549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3JPBFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2590154991","title":"Tenaya Therapeutics Inc - Does Not Expect Hold to Impact Data Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154991?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA3JPBFL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2590603549","title":"Tenaya Therapeutics Inc - Tn-401 Well Tolerated at 3E13 Vg/Kg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2590603549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590603549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2590549679","title":"Tenaya Therapeutics Inc: Robust Transduction and Demonstrated Increases in Pkp2 Protein Levels in First Two Patients at Week 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549679?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2590496785","title":"Tenaya Therapeutics Inc - Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients With More Than Six Months of Follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590496785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590496785?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2590549965","title":"Press Release: Oruka Therapeutics Announces New Board Member and Board Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549965?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Dec. 11, 2025  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis , today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025.\"As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka,\" said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. \"Chris's expertise can bring tremendous value to the company as we advance towards late-stage development and think more concretely about how ORKA-001 and -002 could enter the market. We have greatly valued Cameron's contributions on our Board in helping to shape our strategy and direction in the early stages of building our company, and I would like to personally thank him on behalf of our Board for hi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","ORKA","LENZ"],"gpt_icon":0},{"id":"2590499345","title":"Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499345?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec. 11, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares , each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.The gross proceeds to Structure Therapeutics from the offering were approximately $747.5 million, before deducting underwriting discounts and commissions and offering expenses.Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Ca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0528227936.USD","LU1732800096.USD","LU1791710582.SGD","LU0006306889.USD","LU0267386448.USD","BK4534","LU1989772923.USD","LU2357305700.SGD","LENZ","IE00BKVL7J92.USD","LU0795875086.SGD","LU1244550494.USD","LU0320765646.SGD","LU0158827781.USD","LU0912757837.SGD","LU1720051108.HKD","LU1668664300.SGD","LU1548497426.USD","BK4516","LU0106261372.USD","LU1244550221.USD","LU2271345857.HKD","BK4139","LU0795875169.SGD","BK4581","LU0098860793.USD","BK4127","LU1244550577.SGD","LU1720051017.SGD","LU0314104364.USD","LU2111349929.HKD","LU1732799900.SGD","LU2028103732.USD","LU2089283258.USD","BK4504","BK4539","LU0882574139.USD","LU0234570918.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","BK4007","LU2089284900.SGD","GPCR","LU2133065610.SGD","LU0557290698.USD","LU1989772840.SGD","LU0106831901.USD","BK4588","LU1074936037.SGD","LU0225283273.USD"],"gpt_icon":0},{"id":"2590415455","title":"Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC","url":"https://stock-news.laohu8.com/highlight/detail?id=2590415455","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590415455?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"TN-401 was Well Tolerated at 3E13 vg/kg doseRobust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden O","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204284/0/en/Tenaya-Therapeutics-Reports-Positive-Interim-Data-from-Cohort-1-of-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Gene-Therapy-for-Adults-with-PKP2-associated-ARVC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2244417387.USD","LU2308191902.HKD","LU0124676726.USD","LU0187121727.USD","ACM","LU2238339852.HKD","TNYA","LU0689626769.HKD","BK4585","BK4139","LU1939255532.USD","BK4007","BK4588","BK4516","LU1861214812.USD","HCM","BK4129","BK4531","LU2298064838.USD","BK4539","LU2360107325.USD","LU1861219969.SGD"],"gpt_icon":0},{"id":"2590654950","title":"What's Going On With The Dip In SentinelOne Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590654950","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590654950?lang=en_us&edition=fundamental","pubTime":"2025-12-12 04:40","pubTimestamp":1765485600,"startTime":"0","endTime":"0","summary":"SentinelOne Inc (NYSE:S) shares are trading lower Thursday. The stock was briefly popping following a bullish report from Citron Research.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/SentinelOneMountain-View--Ca--Usa---Feb-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/SentinelOneMountain-View--Ca--Usa---Feb-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49347251/whats-going-on-with-the-dip-in-sentinelone-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49347251/whats-going-on-with-the-dip-in-sentinelone-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0889566641.SGD","IE00BFMHRM44.USD","LU0234572021.USD","LU2506952097.USD","LU2506951875.HKD","LU2506951958.HKD","SG9999015986.USD","LU2237443382.USD","BK4588","BK4539","LU1674673428.USD","LU2506952170.USD","LU1823568750.SGD","LU1894683348.USD","SG9999001440.SGD","BK4585","LU1066051498.USD","IE00BZ1G4Q59.USD","LU1046421795.USD","LU0950375773.USD","CSCO","LU1244550577.SGD","IE00BVYPNW00.USD","LU1032955483.USD","BK4515","LU1506573853.SGD","LU1880398471.USD","LU0320765646.SGD","LU2247934214.USD","SG9999015952.SGD","SG9999001424.SGD","LU1267930813.SGD","LU1066053197.SGD","LU2237443895.HKD","LU0823417737.USD","BK4527","LU1244550221.USD","S","LU0348723411.USD","IE00B1BXHZ80.USD","LU2237443465.HKD","LU1430594728.SGD","LU1674673691.USD","LU2237443622.USD","LU1585245621.USD","SG9999015945.SGD","IE00BSNM7G36.USD","LU1059921491.USD","LU2417539215.USD","BK4525"],"gpt_icon":0},{"id":"2590465895","title":"Prediction Markets Form Lobbying Group as State Pressure Ramps Up -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2590465895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590465895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:45","pubTimestamp":1765482300,"startTime":"0","endTime":"0","summary":"The prediction-market platforms Kalshi and Crypto.com are fighting back against state efforts to regulate their businesses via a new national lobbying group, the Coalition for Prediction Markets.\"The U.S. is the biggest frontier for prediction markets, and the momentum we're seeing makes a unified industry voice not just important, but necessary,\" Matt David, an executive board member of the coalition and chief corporate affairs officer at Crypto.com, said in a news release on Thursday announcing the formation of the group.The organization will be \"dedicated to preserving safe, transparent, and federally supervised access to prediction markets,\" the release said. The coalition is being launched \"as several state casino regulators attempt to extend their authority into a space long governed under federal law,\" it said.This week, gambling regulators in Washington state became the latest to oppose prediction markets. \"Offering events-based contracts or participating in these markets is no","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4516","IE0034235188.USD","BK4547","BK4551","LU1883839398.USD","BK4565","LU1894683348.USD","LU0240877869.USD","IE00BGHQF748.EUR","BK4535","LU1861217088.USD","LU1861558580.USD","BK4588","BK4600","LU1861559042.SGD","LU0240878834.USD","IE00B3QW5Z07.USD","BK4595","BK4596","BK4150","BK4135","BK4112","IE00B64PRP62.GBP","BK4585","COIN","DKNG","LU1169589451.USD","BK4554","HOOD","BK4127","LU1894683264.USD","LU0061475181.USD","LU1861220207.SGD","BK4539","LU2360107671.USD"],"gpt_icon":1},{"id":"2590546849","title":"JP Morgan Issues $50 Million Commercial Paper Debt On Solana","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546849","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546849?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:19","pubTimestamp":1765480743,"startTime":"0","endTime":"0","summary":"JP Morgan Chase &amp; Co (NYSE:JPM) has taken ","market":"us","thumbnail":"https://www.benzinga.com/files/images/story/2025/12/11/JPMorgan-Chase--Co-.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2025/12/11/JPMorgan-Chase--Co-.jpeg"],"rights":{"source":"Benzinga","url":"https://www.benzinga.com/crypto/cryptocurrency/25/12/49345221/jp-morgan-issues-50-million-commercial-paper-debt-on-solana","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/25/12/49345221/jp-morgan-issues-50-million-commercial-paper-debt-on-solana","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["IE00BDCRKT87.USD","LU2746668461.USD","LU1861558580.USD","IE00BKDWB100.SGD","IE00BJTD4N35.SGD","LU1162221912.USD","LU2381873111.SGD","LU1791710400.SGD","LU2505996509.AUD","BK4516","IE00BYXW3230.USD","LU1732799900.SGD","IE0034235303.USD","LU2211815571.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU1116320737.USD","LU1917777945.USD","LU0345769631.USD","BK4554","LU0345770993.USD","LU0251132253.USD","SOL","IE0034235188.USD","LU0912757837.SGD","LU2089284900.SGD","LU2237443382.USD","LU0820562030.AUD","LU1363072403.SGD","LU0795875169.SGD","LU1894683348.USD","LU0820561818.USD","LU0795875086.SGD","BK4596","LU1791710582.SGD","LU2023251221.USD","LU0211331839.USD","LU2756315664.SGD","IE00B775SV38.USD","IE00B1XK9C88.USD","IE00BLSP4452.SGD","IE00BKVL7J92.USD","LU0203345920.USD","LU1074936037.SGD","LU2462157665.USD","LU1496350171.SGD","LU0820561909.HKD","LU2756315318.SGD","LU0211326839.USD","LU0971096721.USD","LU2023250330.USD","LU0211326755.USD","LU0256863811.USD","LU1267930490.SGD","SG9999002232.USD","IE00BLSP4239.USD","LU1244550577.SGD","LU2237443895.HKD","LU2237443549.SGD","BK4207","BK4581","LU0683600562.USD","LU1668664300.SGD","IE00BBT3K403.USD","LU0158827781.USD","LU1974910355.USD","BK4533","LU0320765646.SGD","LU1670627923.USD","BK4535","LU1629891620.HKD","LU2417539215.USD","LU0211328371.USD","LU1548497426.USD","IE00BHPRN162.USD","LU0345770308.USD","LU1894683264.USD","LU2237443978.SGD","LU2456880835.USD","BK4600","LU0265550359.USD","BK4550","LU1861217088.USD","LU2023250504.SGD","LU2360107671.USD","LU2430703178.SGD","LU2347655156.SGD","LU2237443465.HKD","LU1032466523.USD","LU0868494708.USD","SG9999002224.SGD","LU1084165304.USD","LU2054465674.USD","LU0314104364.USD","LU0234572021.USD","BTC.USD.HKCC","LU0208291251.USD","BK4534","IE00BFXG1179.USD","IE000M9KFDE8.USD","LU0267386448.USD","SOL.USD.HKCC","LU0106261372.USD","LU1720051017.SGD","LU2028103732.USD","LU1244550221.USD","LU1989772923.USD","BK4588","IE00B1BXHZ80.USD","LU0345769128.USD","LU0203347892.USD","LU0868494617.USD","LU1119994496.HKD","LU0528227936.USD","LU0215105999.USD","LU0234570918.USD","LU1861220207.SGD","LU1244550494.USD","LU1720051108.HKD","LU1732800096.USD","LU2237443622.USD","LU0048584097.USD","LU1551013342.USD","LU2242649171.HKD","LU2264538146.SGD","LU0238689110.USD","LU0689472784.USD","LU1496350502.SGD","LU0557290698.USD","LU1261432733.SGD","LU0265550946.USD","LU0098860793.USD","LU0640476718.USD","LU1551013425.SGD","LU1914381329.SGD","LU1988902786.USD","LU0976567544.SGD","LU0106831901.USD","LU2357305700.SGD","LU2552382058.USD","LU2133065610.SGD","BK4127","LU2271345857.HKD","LU2111349929.HKD","LU0943347566.SGD","LU2213496289.HKD","LU1989772840.SGD","IE00BWXC8680.SGD","LU2106854487.HKD","LU0158827948.USD","LU2236285917.USD","LU2089283258.USD","LU0942090050.USD","LU1280957306.USD","LU2592432038.USD","LU2505996681.GBP","BK4539","IE00B3S45H60.SGD","LU0006306889.USD","IE0034235295.USD","IE00BJLML261.HKD","LU0310799852.SGD","LU0787776722.HKD","LU0496365809.HKD","IE00BJTD4V19.USD","LU2430703095.HKD","LU2023250843.SGD","BK4112","LU0417517546.SGD","IE00BDRTCR15.USD","LU2746668974.SGD","LU2552382215.SGD","LU0964807845.USD","LU2430703251.USD","BK4504","LU1366192091.USD","IE00BN8TJ469.HKD","LU0170899867.USD","LU1064131342.USD","LU0070302665.USD","JPM","LU2552382132.HKD","LU1145028129.USD","LU1861559042.SGD","BK4566","LU1116320901.HKD","LU1670628061.USD","LU0149725797.USD","LU0225283273.USD","BK4551","LU0211327993.USD","LU0320765489.SGD","BK4595","LU0323591593.USD","BK4585"],"gpt_icon":1},{"id":"2590455815","title":"XRP Gets Yet Another ETF, But $2 Looks Like It's About To Break","url":"https://stock-news.laohu8.com/highlight/detail?id=2590455815","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590455815?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:34","pubTimestamp":1765478040,"startTime":"0","endTime":"0","summary":"21Shares on Thursday launched its new XRP (CRYPTO: XRP) ETF on CBOE under the ticker TOXR, entering the market on a day when major altcoins like","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Heres-What-XRP-Would-Have-Returned.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Heres-What-XRP-Would-Have-Returned.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/crypto/cryptocurrency/25/12/49344015/xrp-gets-yet-another-etf-but-2-looks-like-its-about-to-break","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/25/12/49344015/xrp-gets-yet-another-etf-but-2-looks-like-its-about-to-break","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4516","BK4585","BK4550","TOXR","LU1861558580.USD","LU1861220207.SGD","BK4595","LU2360107671.USD","LU1861217088.USD","BK4588","BK4600","BK4551","LU1861559042.SGD","BK4554","BK4535","BK4112","BK4539","XRP.USD.CC","BK4596"],"gpt_icon":1},{"id":"2590545092","title":"How Weak November Metrics and Connecticut Probe At Robinhood (HOOD) Have Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545092","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545092?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:31","pubTimestamp":1765477879,"startTime":"0","endTime":"0","summary":"Earlier this week, Robinhood Markets reported weak November 2025 operating data, including sharp month‑over‑month drops in equity, options, and crypto trading volumes and a reduction in funded customers, while also facing a Connecticut cease‑and‑desist order over alleged unlicensed online gambling operations.\nBeyond the headline volume declines, the combination of softer user activity and fresh regulatory scrutiny raises questions about the durability of Robinhood’s recent expansion into new...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice1-main-header/1585186724276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice1-main-header/1585186724276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-hood/robinhood-markets/news/how-weak-november-metrics-and-connecticut-probe-at-robinhood","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-hood/robinhood-markets/news/how-weak-november-metrics-and-connecticut-probe-at-robinhood","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","HOOD","BK4539","BK4547","LU1861559042.SGD","BK4127"],"gpt_icon":1}],"pageSize":20,"totalPage":50,"pageCount":19,"totalSize":992,"code":"91000000","status":"200"}]}}